BridgeBio Pharma, Inc.
BBIO
$45.95
$1.142.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 110.57M | 116.63M | 5.88M | 2.73M | 2.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.57M | 116.63M | 5.88M | 2.73M | 2.17M |
| Cost of Revenue | 3.65M | 2.64M | 2.08M | 598.00K | 598.00K |
| Gross Profit | 106.91M | 113.99M | 3.80M | 2.13M | 1.57M |
| SG&A Expenses | 129.15M | 106.37M | 94.78M | 68.82M | 59.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 244.04M | 220.44M | 227.22M | 189.86M | 174.82M |
| Operating Income | -133.47M | -103.80M | -221.33M | -187.13M | -172.65M |
| Income Before Tax | -181.66M | -169.61M | -266.24M | -164.25M | -75.54M |
| Income Tax Expenses | 2.10M | -- | 1.15M | -- | -- |
| Earnings from Continuing Operations | -183.76M | -169.61M | -267.39M | -164.25M | -75.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.86M | 2.19M | 2.34M | 2.21M | 2.09M |
| Net Income | -181.90M | -167.42M | -265.05M | -162.04M | -73.46M |
| EBIT | -133.47M | -103.80M | -221.33M | -187.13M | -172.65M |
| EBITDA | -132.16M | -102.52M | -219.97M | -185.59M | -171.07M |
| EPS Basic | -0.95 | -0.88 | -1.40 | -0.86 | -0.39 |
| Normalized Basic EPS | -0.58 | -0.47 | -0.85 | -0.69 | -0.65 |
| EPS Diluted | -0.95 | -0.88 | -1.40 | -0.86 | -0.39 |
| Normalized Diluted EPS | -0.58 | -0.47 | -0.85 | -0.69 | -0.65 |
| Average Basic Shares Outstanding | 190.52M | 190.15M | 189.44M | 188.51M | 187.59M |
| Average Diluted Shares Outstanding | 190.52M | 190.15M | 189.44M | 188.51M | 187.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |